Temporin A alone and in combination with imipenem reduces lethality in a mouse model of staphylococcal sepsis

Journal of Infectious Diseases

Volumn 192, Issue 9, 2005, Pages 1613-1620

  Cirioni, Oscar ^a   Giacometti, Andrea ^a,c   Ghiselli, Roberto ^a   Kamysz, Wojciech ^b   Orlando, Fiorenza ^a   Mocchegiani, Federico ^a   Silvestri, Carmela ^a   Licci, Alberto ^a   Łukasiak, Jerzy ^b   Saba, Vittorio ^a   Scalise, Giorgio ^a  

^a UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^b MEDICAL UNIVERSITY OF GDANSK   (Poland)

^c Ospedale Regionale Torrette   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; IMIPENEM; INTERLEUKIN 6; LIPOTEICHOIC ACID; NITRIC OXIDE; PEPTIDE; SODIUM CHLORIDE; TEMPORIN A; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIAL COUNT; BACTERIAL GROWTH; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG POTENTIATION; IN VITRO STUDY; LETHALITY; MACROPHAGE; MALE; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SEPSIS; SEPTIC SHOCK; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION;

ANIMALS; ANTI-BACTERIAL AGENTS; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; DRUG THERAPY, COMBINATION; IMIPENEM; MALE; MICE; MICE, INBRED BALB C; PROTEINS; SEPSIS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; TREATMENT OUTCOME;

EID: 27144525263     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/496888     Document Type: Article

References (36)

1. Petti CA, Fowler VG Jr. Staphylococcus aureus bacteremia and endocarditis. Cardiol Clin 2003; 21:219-33.
2. Edgeworth JD, Treacher DF, Eykyn SJ. A 25-year study of nosocomial bacteremia in an adult intensive care unit. Crit Care Med 1999; 27: 1421-8.
3. Wenzel RP, Pinsky MR, Ulevitch RJ, et al. Current understanding of sepsis. Clin Infect Dis 1996; 22:407-13.
4. Angus DC, Linde-Zwirble WT, Lidicker J, et al. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated cost of care. Crit Care Med 2001; 29:1303-10.
5. Centers for Disease Control and Prevention. Staphylococcus aureus with reduced susceptibility to vancomycin-Illinois, 1999. MMWR Morb Mortal Wkly Rep 2000; 48:1165-7.
6. Tenover FC. Implications of vancomycin resistant Staphylococcus aureus. J Hosp Infect 1999; 43(Suppl):S3-7.
7. Raad I, Alrahwan A, Rolston K. Staphylococcus epidermidis emerging resistance and need for alternative agents. Clin Infect Dis 1998; 26: 1182-7.
8. Costa SF, Miceli MH, Anaissie EJ. Mucosa or skin as source of coagulase-negative staphylococcal bacteremia. Lancet Infect Dis 2004; 4: 278-86.
9. Bone RC. Gram-positive organisms and sepsis. Arch Intern Med 1994; 154:26-34.
10. De Kimpe SJ, Kengatharan M, Thiemermann C, et al. The cell wall components peptidoglycan and lipoteichoic acid from Staphylococcus aureus act in sinergy to cause shock and multiple organ failure. Proc Natl Acad Sci USA 1995; 92:10359-63.
11. Tarkowski A, Collins LV, Jonsson IM, et al. Microbial superantigens as virulence factors and ways to counteract their actions. Scand J Infect Dis 2003; 35:642-6.
12. Heumann D, Barras C, Severin A, et al. Gram-positive cell walls stimulate synthesis of tumor necrosis factor alpha and interleukin-6 by human monocytes. Infect Immun 1994; 62:2715-21.
13. Baker MD, Acharya KR. Superantigens: structure-function relationships. Int J Med Microbiol 2004; 293:529-37.
14. Kengatharan M, De Kimpe SJ, Robson C, et al. Mechanism of Gram-positive shock: identification of peptidoglycan and lipoteichoic acid mioeties essential in the induction of nitric oxide synthase, shock, and multiple organ failure. J Exp Med 1998; 188:305-15.
15. Llewelyn M, Cohen J. Superantigens: microbial agents that corrupt immunity. Lancet Infect Dis 2002; 2:156-62.
16. Scott MG, Gold MR, Hancock REW. Interaction of cationic peptides with lipoteichoic acid and gram-positive bacteria. Infect Immun 1999; 67:6445-53.
17. Akashi S, Saitoh S, Wakabayashi Y, et al. Lipopolysaccharide interaction with cell surface Toll-like receptor 4-MD-2: higher affinity than that with MD-2 or CD14. J Exp Med 2003; 198:1035-42.
18. Cannon M. A family of wound healers. Nature 1987; 328:478.
19. Hancock REW, Scott MG. The role of antimicrobial peptides in animal defenses. Proc Natl Acad Sci USA 2000; 97:8856-61.
20. Bevins CL, Zasloff M. Peptides from frog skin. Ann Rev Biochem 1990; 59:395-414.
21. Harjunpää I, Kuusela P, Smoluch MT, et al. Comparison of synthesis and antibacterial activity of temporin A. FEBS Lett 1999; 449:187-90.
22. Simmaco M, Mignogna G, Canofeni S, et al. Temporins, antimicrobial peptides from the European red frog Rana temporaria. Eur J Biochem 1996; 242:788-92.
23. Chen Q, Wade D, Kurosaka K, et al. Temporin A and related frog antimicrobial peptides use formyl peptide receptor-like 1 as a receptor to chemoattract phagocytes. J Immunol 2004; 173:2652-9.
24. Vojkovsky T. Detection of secondary amines on solid phase. Pept Res 1995; 8:236-7.
25. National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically: approved standard M7-A6. Villanova, PA: National Committee for Clinical Laboratory Standards, 2003.
26. Eliopoulos GM, Moellering RC Jr. Antimicrobial combinations. In: Lorian V, ed. Antibiotics in laboratory medicine. Baltimore: Williams & Wilkins, 1996:330-93.
27. Van Amersfoort ES, Van Berkel TJC, Kuiper J. Receptors, mediators, and mechanisms involved in bacterial sepsis and septic shock. Clin Microbiol Rev 2003; 16:379-414.
28. Llewlyn M, Cohen J. Superantigen antagonist peptides. Crit Care 2001; 5:53-5.
29. Visvanathan K, Charles A, Bannan J, et al. Inhibition of bacterial superantigens by peptides and antibodies. Infect Immun 2001; 69:875-84.
30. Timmerman CP, Mattsson E, Martinez-Martinez L, et al. Induction of release of tumor necrosis factor from human monocytes by staphylococci and staphylococcal peptidoglycans. Infect Immun 1993; 61:4167-72.
31. Prins JM, Kuijper EJ, Mevissen MLCM, et al. Release of tumor necrosis factor alpha and interleukin 6 during antibiotic killing of Escherichia coli in whole blood: influence of antibiotic class, antibiotic concentration, and presence of septic serum. Infect Immun 1995; 63:2236-42.
32. Byl B, Clevenbergh P, Kentos A, et al. Ceftazidime- and imipenem-induced endotoxin release during treatment of gram-negative infections. Eur J Clin Microbiol Infect Dis 2001; 20:804-7.
33. Fernandez-Cuenca F, Martinez-Martinez L, Conejo MC, et al. Relation between beta-lactamase production, outer membrane protein and penicillin-binding protein profiles on the activity of carbapenems against clinical isolates of Acinetobacter baumannii. J Antimicrob Chemother 2003; 51:565-74.
34. Sahl HG, Jack RW, Bierbaum G. Biosynthesis and biological activities of lantibiotics with unique post-translational modifications. Eur J Biochem 1995; 230:827-53.
35. Giacometti A, Cirioni O, Ghiselli R, et al. Administration of protegrin peptide IB-367 to prevent endotoxin-induced mortality in bile duct-ligated rats. Gut 2003; 52:874-8.
36. Wade D, Silveira A, Rollins-Smith L, et al. Hematological and antifungal properties of temporin A and a cecropin A-temporin A hybrid. Acta Biochim Pol 2001; 48:1185-9.